Roche, Novartis move Xolair closer to FDA finish line for food allergies
Fierce Pharma
DECEMBER 19, 2023
On the market for two decades for asthma, Novartis and Roche’s Xolair is closing in on a new indication as a way for those with food allergies to avoid severe outcomes. | The agency granted a priority review to Roche's filing and plans to make a decision during the first quarter of next year.
288 
Let's personalize your content